Moderate to severe
Vasomotor Symptoms,
also known as VMS or hot flashes and night sweats,
are the most bothersome symptoms of menopause.
Growing evidence
has led to a different treatment pathway
that directly targets
a source of VMS in the hypothalamus.
Meet VEOZAH (fezolinetant).
VEOZAH is not a hormone.
It is a first-in-class
NK3R antagonist
that works differently
to directly block a mechanism that triggers VMS.
KNDy neurons in the hypothalamus
are inhibited by estrogen
and stimulated by the neuropeptide, NKB.
This balance contributes to
body temperature regulation.
During the menopause transition,
estrogen decline disrupts this balance
with NKB.
Unopposed,
NKB signaling
causes heightened KNDy activity
and altered activity on the thermoregulatory center,
resulting in VMS.
VEOZAH
directly targets this source of VMS.
By selectively binding to NK3R,
VEOZAH blocks NKB,
modulating neuronal activity
in the thermoregulatory center
to reduce heat signaling that triggers
hot flashes and night sweats.
It's time to put the mechanism of VEOZAH to work
for your appropriate VMS patients.